New drug trial for tough pancreatic cancer halted before it began
Disease control
Terminated
This study was designed to test a new drug, GFH375, in people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D) and has already been treated. The goal was to see if the drug could shrink tumors or slow the disease. However, the trial was withdrawn bef…
Phase: PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC